Eli Lilly’s oral selective estrogen receptor degrader (SERD) Inluriyo (imlunestrant) received FDA approval for treating metastatic estrogen receptor-positive, HER2-negative breast cancer in patients harboring ESR1 mutations after progression on hormone therapy. This oral therapy is part of a new wave of SERDs, aiming to replace older injectable treatments such as fulvestrant. Approval was supported by the EMBER-3 study showing that Inluriyo significantly delayed disease progression and was generally well tolerated, marking a vital step toward all-oral breast cancer treatment regimens.